Drug intelligence / Profile preview

TML-CEM-19

Development stage: Preclinical
Lead developer: Themis Medicare
Modality: Small Molecules

Overview

TML-CEM-19 is a preclinical-stage long-acting vitamin formulation being developed by Themis Medicare. It utilizes a Novel Drug Delivery System (NDDS) to provide sustained release of vitamins, potentially reducing the frequency of administration and improving patient compliance. The specific vitamins included in the formulation are not publicly disclosed, but the product is part of Themis Medicare's innovation pipeline focused on differentiated parenterals and advanced delivery technologies. The development aims to address nutritional deficiencies through improved pharmacokinetic profiles.

Other names: Long Acting Vitamins

Beyond the preview

Go deeper on TML-CEM-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TML-CEM-19.

Explore the full profile